Psychedelics fact sheet

A short summary of what we know todaya on classical psychedelics for the treatment of depression

Fact 1: 5-HT2A receptor binding

Fact 2: Changes in default mode network

Fact 3: Impact on neuroplasticity

Fact 4: Clinical effects

Fact 5: Side effects and safety

grid_view

out of/ 9

Slide description

Full description, scroll

file_download Download slide in HQ file_downloadDownload all in HQ

This slide deck summarizes the current knowledge surrounding the use of psychedelics for the treatment of depression. Specifically, our focus centers on serotonergic psychedelics, commonly referred to as classical psychedelics. These psychedelics primarily function as agonists or partial agonists at the serotonin 2A receptor (5-HT2A receptor).

This slide deck has been developed with Professor Gitte Moos Knudsen, University of Copenhagen, Denmark, and Professor David Nutt, Imperial College London, UK, and in collaboration with Cambridge (a division of Prime, Cambridge, UK).

file_download Download slide in HQ file_downloadDownload all in HQ

Index for
slide deck

Introduction

A short summary of what we know todaya on classical psychedelics for the treatment of depression

A short summary of what we know todaya on classical psychedelics for the treatment of depression

file_download Download slide in HQ

The focus

The focus

References:
1. Butlen-Ducuing F, McCulloch DE, Haberkamp M, et al. The therapeutic potential of psychedelics: the European regulatory perspective. Lancet 2023; 401 (10378): 714–716.

2. Kelmendi B, Kaye AP, Pittenger C, Kwan AC. Psychedelics. Curr Biol 2022; 32 (2): R63–R67…

file_download Download slide in HQ

Glossary

Glossary

Glossary

References:
1. Hoyer D, Clarke DE, Fozard JR, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev 1994; 46 (2): 157–203.

2. Miranda M, Morici JF, Zanoni MB, Bekinschtein P. Brain-derived neurotrophic fac…

file_download Download slide in HQ

Psychedelic fact sheet

Fact 1: 5-HT2A receptor binding

Fact 1: 5-HT2A receptor binding

References:
1. CAS Common chemistry. Serotonin. Available at: https://commonchemistry.cas.org/detail?cas_rn=50-67-9&search=serotonin. Accessed 11 Oct 2023.

2. CAS Common chemistry. (+)-Lysergic acid diethylamide. Available at: https://commonchemistry.cas.org/detail?cas_rn=…

file_download Download slide in HQ

Fact 2: Changes in default mode network

Fact 2: Changes in default mode network

References:
1. University of California San Francisco (UCSF). Psilocybin rewires the brain for people with depression. Available at: https://www.ucsf.edu/news/2022/04/422606/psilocybin-rewires-brain-people-depression. Accessed 21 October 2023.

2. Daws RE, Timmermann C, Gir…

file_download Download slide in HQ

Fact 3: Impact on neuroplasticity

Fact 3: Impact on neuroplasticity

References:
1. Ray MT, Shannon Weickert C, Webster MJ. Decreased BDNF and TrkB mRNA expression in multiple cortical areas of patients with schizophrenia and mood disorders. Transl Psychiatry 2014; 4 (5): e389.

2. Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic…

file_download Download slide in HQ

Fact 4: Clinical effects

Fact 4: Clinical effects

References:
1. Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med 2021; 384 (15): 1402–1411.

2. Davis AK, Barrett FS, May DG, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a rand…

file_download Download slide in HQ

Fact 5: Side effects and safety

Fact 5: Side effects and safety

References:
1. Schlag AK, Aday J, Salam I, et al. Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. J Psychopharmacol 2022; 36 (3): 258–272.

2. Nutt D, Spriggs M, Erritzoe D. Psychedelics therapeutics: what we know, what we think, an…

file_download Download slide in HQ

Conclusions

Conclusions

Conclusions

Reference:
1. Butlen-Ducuing F, McCulloch DE, Haberkamp M, et al. The therapeutic potential of psychedelics: the European regulatory perspective. Lancet 2023; 401 (10378): 714–716.

2. Nutt D, Spriggs M, Erritzoe D. Psychedelics therapeutics: what we know, what we think, an…

file_download Download slide in HQ

task_alt